Véronique Debien, Medical Oncologist at Institute Bergonié, shared a post on LinkedIn:
“Back from ESMO25 with both data and direction. Proud that our Institut Bergonié early-phase unit contributed to several phase I/II trials:
- START-01 / invikafusp alfa – TCR-β-chain–targeting bispecific in ICB-resistant solid tumors (presented by Italiano Antoine)
- HRO761 / WRN helicase inhibitor – first-in-human, MSI-H/dMMR dose-escalation (presented by Michael Foote)
- Olomorasib (LOXO-RAS) – intracranial efficacy in KRAS G12C NSCLC w/ active untreated brain metastases (presented by CASSIER Philippe)
- PIKALO-1 (STX-478 / LY4064809) – pan-mutant-selective PI3Kα inhibition, updated expansion data (presented by @Dejan Jurić)
- DAREON-8 (obrixtamig + chemo + atezolizumab) – 1L ES-SCLC phase I (presented by Peters Solange)
And many other programs where the first patients were dosed in our unit were shown for the first time.
Innovation is exciting, but we remind ourselves constantly that behind every bar on a waterfall plot there is a person, a family, a life-project on hold. That is our why.
We leave ESMO25 not only with data and direction, but with renewed commitment to build options where today there are none.
The pipeline coming to first-in-human tomorrow becomes the standard of care for someone later and our role is to compress that timeline responsibly, ethically, rigorously, fast.
Closing with today’s rainbow over our institution – a fitting symbol of possibility made of science, collaboration and trust.”
You can also read:
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
ESMO 2025 Day 3 Highlights Not to Miss
ESMO 2025 Day 4 Highlights Not to Miss
ESMO 2025 Day 5 Highlights Not to Miss
